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PURPOSE. We provide a standardized set of terminology, definitions, and thresholds of myopia
and its main ocular complications.
METHODS. Critical review of current terminology and choice of myopia thresholds was done to
ensure that the proposed standards are appropriate for clinical research purposes, relevant to
the underlying biology of myopia, acceptable to researchers in the field, and useful for
developing health policy.
RESULTS. We recommend that the many descriptive terms of myopia be consolidated into the
following descriptive categories: myopia, secondary myopia, axial myopia, and refractive
myopia. To provide a framework for research into myopia prevention, the condition of ‘‘pre-
myopia’’ is defined. As a quantitative trait, we recommend that myopia be divided into myopia
(i.e., all myopia), low myopia, and high myopia. The current consensus threshold value for
myopia is a spherical equivalent refractive error  0.50 diopters (D), but this carries
significant risks of classification bias. The current consensus threshold value for high myopia
is a spherical equivalent refractive error  6.00 D. ‘‘Pathologic myopia’’ is proposed as the
categorical term for the adverse, structural complications of myopia. A clinical classification is
proposed to encompass the scope of such structural complications.
CONCLUSIONS. Standardized definitions and consistent choice of thresholds are essential
elements of evidence-based medicine. It is hoped that these proposals, or derivations from
them, will facilitate rigorous, evidence-based approaches to the study and management of
myopia.
Keywords: myopia, myopia classification, myopia definitions, high myopia, myopia
thresholds, high myopia, pathologic myopia
1. INTRODUCTION
Myopia currently is widely recognized as a significant publichealth issue causing significant visual loss and a risk factor
for a range of other serious ocular conditions.1 The prevalence
of this condition is increasing on a global basis, for reasons that
still are not understood.2 Although partial reductions in
progression rates have been observed from pharmacologic
therapies, optical treatments, and behavioral modifications3
(see also accompanying paper IMI – Interventions for
Controlling Myopia Onset and Progression Report),4 we are a
long way from being able to reverse the temporal trends of the
last few decades. This makes myopia, and its associated
complications, a high research priority.
Myopia has been the subject of scientific study since the
work of Johannes Kepler in 1604, and a topic of philosophic
discussion from the time of Aristotle. Over the intervening
centuries, myopia has been defined in a wide variety of ways:
presumed etiology, age of onset, progression pattern, amount of
myopia (in diopters [D]) and structural complications. This has
led to an excessive and confusing accumulation of terms. Table
1 lists some of the terms and concepts that have been used in
classifying myopia as a function of these five categories. As
shown in this table, several terms have been used in ways that
relate to more than one category; that is, to describe the
presumed etiology as well as the severity or amount of myopia.
Transient forms of myopia that often are termed pseudo myopia
(e.g., instrument myopia, night myopia, or accommodative
spasm) are not included in this Table.
The extensive literature regarding the etiology of refractive
errors has revealed a complex picture. It is clear that myopia is
a multifactorial condition, and that any classification based on
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simple etiologic factors is likely to be an over-simplification at
best and misleading at worst. Time of onset also is of
questionable value, since we do not yet know whether the
biological processes underlying myopia at age 7 differ from
those in myopia that develop in early adults. There also is
considerable variation in the age at onset of myopia and its
progression in different geographic regions.5 Terms that are
used commonly to describe the anatomic complications,6
notably ‘‘pathologic myopia’’ or its alternative spelling
‘‘pathological myopia,’’ also are used to describe higher
degrees of myopia based on refractive error, even in the
absence of structural complications.7 Furthermore, the struc-
tural complications of high myopia have been demonstrated to
be highly age-dependent,8 so relying on a dioptric threshold for
pathologic myopia is problematic. Such terms as ‘‘physiologic
myopia’’ also are used in relation to etiology and severity of
myopia. In addition, this term carries the implication that such
myopia, being physiologic, is devoid of any adverse conse-
quence, which is a misleading inference.9
In this era of evidence-based medicine, the accumulation of
different terms and classifications is a significant hindrance.
There also is considerable variation in defining myopia in terms
of dioptric error. Such inconsistency creates challenges when
comparing epidemiologic studies. Meta-analysis of randomized
controlled trials can be weakened by variations in the inclusion
criteria and definitions. Standardized, international classifica-
tions are an essential feature of the evidence-based approach,
as demonstrated in fields, such as retinopathy of prematurity
and diabetic retinopathy. To date, the myopia field has lacked a
similar set of internationally agreed standards. We propose a set
of definitions for myopia that are evidence-based, statistically
sound, and clinically relevant.
This initiative arose from the work of the International
Myopia Institute (IMI) and the international committee
responsible for producing this study includes researchers in a
wide range of fields: pediatric ophthalmology, epidemiology,
public health, optometry, clinical myopia research, and
medical retina. Input also was received from a large number
of researchers within this field who are affiliated with the IMI.
It is hoped that these proposals, or derivations from them, will
facilitate rigorous, evidence-based approaches to the study and
management of myopia.
2. RATIONALIZATION OF MYOPIC TERMINOLOGY
We propose that many of the descriptive terms within Table 1
should be abandoned, and a simpler set of terms be adopted, as
shown in Tables 2 and 3. Five fundamental aspects of myopia
should be covered by any set of terminology: optics, etiology
(if known), diagnostic thresholds, progression, and structural
complications.
There is wide consensus in defining myopia optically in
relation to the formation of the retinal image, though the
precise choice of words does vary. The current version of the
World Health Organization’s (WHO) International Classifica-
tion of Disease (ICD-10) provides the following definition for
myopia:
TABLE 1. Descriptive Terms Used to Describe Various Subtypes of
Myopia According to Classification Based on Presumed Etiology, Age of
Onset, Progression, Amount of Myopia and Structural Complications
Basis of
Classification
Associated Descriptive Terms for
Different Types of Myopia




Age at onset Childhood, congenital, acquired, juvenile
onset, youth onset, school, adult, early
adult onset, late adult onset
Progression pattern Permanently progressive, progressive,
progressive high, progressive high
degenerative, stationary, temporarily
progressive




Structural complications Degenerative, degenerative high,
malignant, pathologic, pathological,
pernicious, progressive, progressive
high, progressive high degenerative




Myopia A refractive error in which rays of light
entering the eye parallel to the optic axis
are brought to a focus in front of the
retina when ocular accommodation is
relaxed. This usually results from the
eyeball being too long from front to back,
but can be caused by an overly curved
cornea and/or a lens with increased
optical power. It also is called
nearsightedness.
Axial myopia A myopic refractive state primarily resulting
from a greater than normal axial length.
Refractive myopia A myopic refractive state that can be
attributed to changes in the structure or
location of the image forming structures
of the eye, i.e. the cornea and lens.
Secondary myopia A myopic refractive state for which a single,
specific cause (e.g., drug, corneal disease
or systemic clinical syndrome) can be
identified that is not a recognized
population risk factor for myopia
development.
Quantitative definitions
Myopia A condition in which the spherical
equivalent refractive error of an eye is
 0.50 D when ocular accommodation
is relaxed.
Low myopia A condition in which the spherical
equivalent refractive error of an eye is
 0.50 and > 6.00 D when ocular
accommodation is relaxed.
High myopia A condition in which the spherical
equivalent refractive error of an eye is
 6.00 D when ocular accommodation
is relaxed.
Pre-myopia A refractive state of an eye of  þ0.75 D
and > 0.50 D in children where a
combination of baseline refraction, age,
and other quantifiable risk factors provide
a sufficient likelihood of the future
development of myopia to merit
preventative interventions.
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A refractive error in which rays of light entering the eye
parallel to the optic axis are brought to a focus in front of
the retina when accommodation (accommodation, ocular)
is relaxed. This results from an overly curved cornea or
from the eyeball being too long from front to back. It also is
called nearsightedness.
The recently released ICD-11 for Mortality and Morbidity
Statistics (2018) includes the same definition (under code
9D00.0). The first sentence of this definition encapsulates the
basic optics of myopia. The second sentence attempts to
define the source of the refractive error, but fails to include the
possible contribution of the lens. It also implies a strict divide
between myopia associated with axial elongation (often
referred to as axial myopia) and myopia associated with
increased optical power of an eye (often referred to as
refractive myopia). To address both issues, the definition
would be made more accurate by omitting the second
sentence or rephrasing as follows:
Myopia: a refractive error in which rays of light entering the
eye parallel to the optic axis are brought to a focus in front
of the retina when ocular accommodation is relaxed. This
usually results from the eyeball being too long from front to
back, but can be caused by an overly curved cornea and/or
a lens with increased optical power. It also is called
nearsightedness.
This proposed definition has been submitted for consider-
ation by the WHO.
3. USEFUL QUALIFYING TERMS FOR MYOPIA
The above definition includes all forms and degrees of myopia,
which is appropriate for a general definition of myopia as a
subcategory of refractive disorders (i.e., category 9D00 within
ICD-11 for Mortality and Morbidity Statistics [2018]). However,
this definition encompasses a heterogeneous group of refrac-
tive errors. For research purposes, additional qualification is
required to ensure that homogenous groups of myopes can be
selected for trials or genetic studies. As indicated above,
myopia can be differentiated into refractive myopia, in which
the optical power of the cornea and/or lens is abnormally high
in eyes with a normal optical axis length, and/or the more
common axial myopia, in which the optical axis is too long in
relation to the refractive power of the cornea and lens. Axial
and refractive myopia often are defined as distinct entities:
axial myopia—a myopic refractive state that can be
attributed to excessive axial elongation
refractive myopia—a myopic refractive state that can be
attributed to changes in the structure or location of the
image forming structures of the eye; that is, the cornea and/
or lens.
While this distinction is useful in certain contexts (such as
in keratoconus or eyes with very long axial lengths), the
refraction of an eye depends on how well matched an eye’s
axial length is to its optical power, and so both factors are
relevant in many eyes. When myopia is progressing, the
distinction between axial and refractive myopia is easier to
make as the axial length and optical power can be monitored
TABLE 3. Definitions for the Structural Complications of Myopia
Term Definition
Descriptive definitions
Pathologic myopia Excessive axial elongation associated with myopia that leads to structural changes in the
posterior segment of the eye (including posterior staphyloma, myopic maculopathy,
and high myopia-associated optic neuropathy) and that can lead to loss of best-
corrected visual acuity.
Myopic macular degeneration (MMD) A vision-threatening condition occurring in people with myopia, usually high myopia that
comprises diffuse or patchy macular atrophy with or without lacquer cracks, macular
Bruch’s membrane defects, CNV and Fuchs spot.
Diagnostic subdivisions of MMD
Myopic maculopathy Category 0: no myopic retinal degenerative lesion.
Category 1: tessellated fundus.
Category 2: diffuse chorioretinal atrophy.
Category 3: patchy chorioretinal atrophy.
Category 4: macular atrophy.
‘‘Plus’’ features (can be applied to any category): lacquer cracks, myopic choroidal
neovascularization, and Fuchs spot.
Presumed myopic macular degeneration A person who has vision impairment and vision acuity that is not improved by pinhole,
which cannot be attributed to other causes, and:
 The direct ophthalmoscopy records a supplementary lens < 5.00 D and shows
changes such as ‘‘patchy atrophy’’ in the retina or,
 The direct ophthalmoscopy records a supplementary lens < 10.00 D.
Specific clinical conditions characteristic of pathologic myopia
Myopic traction maculopathy (MTM) A combination of macular retinoschisis, lamellar macula hole and/or foveal retinal
detachment (FRD) in eyes with high myopic attributable to traction forces arising from
adherent vitreous cortex, epiretinal membrane, internal limiting membrane, retinal
vessels, and posterior staphyloma.
Myopia-associated glaucoma-like optic neuropathy Optic neuropathy characterized by a loss of neuroretinal rim and enlargement of the
optic cup, occurring in eyes with high myopia eyes with a secondary macrodisc or
peripapillary delta zone at a normal IOP.
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with biometric techniques (see accompanying paper, IMI –
Clinical Myopia Control Trials and Instrumentation Report).10
Clinical trials and work with animal models of myopia have
provided ample evidence that axial elongation is the primary
factor driving myopic progression; when comparing interven-
tion to reduce myopic progression, there is a clear relationship
between the impact of an intervention on refraction and axial
length.3 Therefore, the inclusion and exclusion criteria of trials
investigating treatments designed to reduce myopic progres-
sion should aim to primarily recruit axial myopes and exclude
subjects with refractive myopia. To that end, many trials now
include evidence of progression as an inclusion criterion, but
additional age-specific normative data of ocular dimensions and
growth patterns would enhance the ability of researchers to
separate these two categories and ensure more homogeneous
study populations. In animal studies, myopia arising from
anterior segment changes (cornea or lens) often is differenti-
ated from that resulting from increased posterior eye growth
by measuring vitreous chamber depth. In clinical studies axial
length is used almost universally. Introducing measurement of
vitreous chamber depth into clinical studies may be a useful
method of identifying myopic progression primarily associated
with axial elongation.
As noted above, for the majority of myopia we cannot
define a precise etiology and, hence, etiologic classifications
currently are premature, but for certain rare forms of myopia a
direct cause can be identified. The concept of primary
compared to secondary myopia11 is lacking in refractive
studies. In comparison, a division into primary and secondary
etiologies is well established in other fields, such as glaucoma.
As is the case for glaucoma, many secondary forms of myopia
exist, including syndromic forms of myopia associated with
known Mendelian gene defects,12,13 myopia arising from
structural abnormalities of the cornea (e.g., keratoconus) or
lens (e.g., microspherophakia), and drug-induced myopia. Such
secondary forms of myopia can be axial and/or refractive. The
term secondary myopia certainly has value, but the use of the
term primary myopia is less obvious. In primary glaucoma no
cause can be identified, whereas in the forms of myopia that
may be considered primary there is a wide range of possible
risk factors though no definite single cause. This means that
secondary myopia is best reserved for situations where a single
causative factor can be identified that is not a known
population risk factor for myopia development. Therefore,
the following definition for secondary myopia is proposed:
Secondary Myopia: a myopic refractive state for which a
single, specific cause (e.g., drug, corneal disease, or
systemic clinical syndrome) can be identified that is not a
recognized population risk factor for myopia development.
4. QUANTITATIVE THRESHOLDS FOR MYOPIA
As well as defining myopia in descriptive terms, specific
dioptric thresholds are required for many research purposes.
This approach has the advantages of being quantitative and
objective. While it may appear to be the simplest and least
controversial means of classification, it is one where a great
amount of inconsistency exists, reflecting the inherent
difficulties in converting a continuous trait into a category of
disease severity. There are wide variations between studies in
choice of threshold, technique for measuring refractive error
(automated refraction versus retinoscopy), use of cycloplegia,
choice of cycloplegic, protocol for administration of cyclople-
gia, choice of refractive parameter to use, and how astigmatism
is handled (e.g., spherical equivalent or least myopic meridian).
As questions of technique and instrumentation for refraction
are being addressed by other studies in this series (see
accompanying study IMI – Clinical Myopia Control Trials and
Instrumentation Report),10 we will concentrate on the
selection of the most appropriate thresholds.
When considering quantitative thresholds and descriptions
of myopia, one issue that warrants standardization is the use of
mathematical comparison symbols (e.g., <, >, , and ‡) and
nonmathematical words indicating a greater or lesser value.
Myopic refractions are best expressed as negative values of
Diopters. This creates potential ambiguities when comparing
degrees of myopia. For example, does ‘‘< 6.00 D’’ mean a
refractive error more myopic than6.00 D or a refractive error
less myopic than 6.00 D? Both interpretations are in
widespread use. Optics is a highly mathematical science and
any quantitative descriptors must be mathematically valid. The
most logically consistent approach is always to treat myopic
refractive errors as negative values and use mathematical terms
in their strict mathematical sense, so < 6.00 D of myopia
means refractive errors with values more minus, and, hence,
more myopic than 6.00 D.
If a description is made in words and mathematical terms
(such as being less than a negative number of diopters), then a
refraction of ‘‘less than 6 D’’ should be described as ‘‘more
myopic.’’ If myopia is described as a positive dioptric value
then the consistent mathematical approach indicates that
‘‘more than 6 D of myopia’’ represents refractions more
myopic than6 D. Similarly, phrases such as ‘‘higher degrees of
myopia’’ should be interpreted as meaning more myopic
prescriptions.
Recommendation: In quantitative contexts, myopia always
should be treated as a negative value and mathematical
comparison symbols should be used in their strict
mathematical sense.
4.1 Myopia, Low Myopia, and High Myopia
We propose that three quantitative categories, at a minimum,
are required to describe the degree of myopia: myopia, low
myopia, and high myopia. These terms are broadly accepted
within this field, but they have no standardized definitions. A
recent report of the WHO14 noted that ‘‘there is currently no
internationally agreed threshold for myopia or for high
myopia.’’ That publication proposed the following definitions,
primarily with the requirements of Rapid Assessment of
Avoidable Blindness in mind:
Myopia is ‘‘a condition in which the spherical equivalent
objective refractive error is  0.50 D in either eye.’’
High Myopia is ‘‘a condition in which the spherical
equivalent objective refractive error is  5.00 D in either
eye.’’
The choice of spherical equivalent as a primary measure is
widely accepted, but by referring to ‘‘either eye,’’ these
definitions are not suitable to studies in which individual eyes
are analyzed. Where both eyes are used in a study, the use of
‘‘either eye’’ to define myopia means that some hyperopic eyes
may be included in a study population of myopes. Further-
more, the term ‘‘objective refractive error’’ introduces a
methodologic aspect into a definition that ideally should be
independent of technique. The choice of thresholds for myopia
and high myopia also is an issue where there is significant
variation within the myopic literature. To ensure that the
definitions of myopia and high myopia have the greatest
acceptability and the most scientific use, the thresholds should
be evidence-based, statistically appropriate, and clinically
relevant. In the following section we provide an evidence-
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based analysis of the thresholds for myopia and high myopia.
Definition of these two thresholds—one for the diagnosis of
myopia and a second for the diagnosis of high myopia—allow
low myopia to be defined as myopia that does not meet the
threshold for high myopia.
4.2 Choice of Diagnostic Threshold for Myopia
To determine the degree of consensus surrounding the choice
of  0.50 D, we analyzed the thresholds used in epidemio-
logic surveys of refractive error and randomized controlled
treatment trials of interventions for reducing myopia progres-
sion. The studies chosen for analysis met the criteria for
inclusion in two recent meta-analyses covering these two
aspects of myopia research and, therefore, have been
prevalidated in terms of study quality.2,3 A full list of these
studies and their references are included in online Appendix 1.
Of the 138 epidemiologic/survey studies identified, 87.7%
used <0.50 D or 0.50 D as the threshold for myopia, with
a clear preference for the inclusive threshold of 0.50 D (see
Fig. 1). From network meta-analysis of intervention trials, 27
studies provided a threshold for myopia (one trial specifically
targeted high myopes so reported no threshold for myopia).
There was greater variation within these 27 studies as shown
in Figure 2. The modal group was still  0.50 D, but many
studies used higher degrees of myopia as an inclusion criterion.
The majority of these studies were conducted and published
before the publication of the WHO report.
For myopia, the evidence points to a preference for using a
refractive threshold of 0.50 D. Although this represents an
existing, informal standard within myopia research, it should
be recognized that, from a statistical perspective, it is a flawed
one. Other thresholds may be more appropriate according to
the research question being addressed by a particular study. A
recent analysis of the impact of different myopic thresholds in
epidemiologic studies showed that even differences as small as
0.25 D could create false-positive and -negative associations for
specific risk factors.15 This occurs because the choice of
threshold determines the composition of both eyes classified as
myopic and non-myopic with respect to the distribution of
putative risk factors. Choice of a low threshold, such as
0.50 D, may make intervention trials that use myopia onset
a primary outcome variable appear more effective, but with a
threshold change to just  0.75 D, the effect may be far
smaller. This was apparent in a recent intervention study of the
effect of increased time outdoors on myopia prevention.16,17
Intervention trials for myopia often include evidence of myopic
progression as an inclusion criterion. This provision may
necessitate a more myopic inclusion threshold. As shown in
Figure 2, for intervention trials there is a second peak in the
distribution at 1.00 to 1.25 D. Finally, the method of
refraction has a bearing on the choice of diagnostic threshold
for myopia. Measurement error must be considered when
selecting a threshold to avoid misclassification. With a more
myopic threshold, such as 0.75 or 1.00 D, the probability
that only ‘‘true’’ myopes are included is increased. Lack of
cycloplegia also introduces a bias toward more myopic
refraction results with a similar risk of misclassification.
Therefore, studies that use noncycloplegic refraction tech-
niques and include younger subjects should consider more
myopic thresholds.
In summary, a refraction of  0.50 D merits selection as
the evidence-based, consensus threshold for the diagnosis of
myopia, but this threshold may not be appropriate for certain
research questions. Where a different threshold is chosen for a
study, investigators should clearly indicate the methodologic
and statistical reasons for their choice. In such cases, a
sensitivity analysis should be performed for the primary
outcomes using the standard  0.50 D threshold cases to
facilitate comparison with other studies whenever possible.
Conversely, if a plausible risk of classification bias exists in a
study, then a sensitivity analysis should be performed at more
myopic thresholds (e.g.,  0.75 or  1.00 D) whenever
possible. This reporting standard ensures the maximal
comparability of different studies, while minimizing the risk
of false-positive and -negative findings due to classification bias.
4.3 Diagnostic Threshold for High Myopia
There is no clear biological basis in terms of axial length,
refraction or other ocular biometric parameter to differentiate
high from lower degrees of myopia. Nevertheless, high myopia
is a widely used concept and must be defined as coherently as
possible. Currently, there is no agreed quantitative threshold
FIGURE 1. Variation in the choice of diagnostic thresholds for myopia in terms of spherical equivalent within epidemiologic studies included in
meta-analysis (n ¼ 138 studies).
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for high myopia. The WHO report14 indicates that the
threshold for high myopia of  5.00 D was chosen because
5.00 D of uncorrected myopia gives an estimated distance
visual acuity of 6/172, a level that meets the threshold for
blindness (<3/60 in the better eye). This approach emphasizes
the impact of uncorrected refractive errors in populations with
poor access to glasses.
Among 59 epidemiologic studies reviewed that reported on
prevalence of high myopia 35.6% used < 5.00 or  5.00 D
and 61% used <6.00 or 6.00 D as the threshold for high
myopia (Fig. 3). For the 25 intervention studies that included a
threshold for high myopia, the most frequent upper inclusion
threshold was ‡ 6.00 D (i.e., highly myopic eyes were
excluded; n¼8, 32%) (Fig. 4). As this represents the upper end
of the inclusion range, high myopia from the perspective of
these trials was < 6.00 D. The second most common upper
threshold for inclusion in the intervention trials was ‡4.0 D.
Overall the evidence-based consensus points to a threshold
of 6.00 D for high myopia. It is less clear-cut whether this
should be an inclusive threshold (i.e.,  6.00 D) or an
exclusive one (< 6.00 D). For consistency with the lower
threshold for myopia, we propose that high myopia be defined
as a refractive error  6.00 D.
However, as noted for the diagnostic threshold for myopia,
the choice of threshold should be appropriate to the research
question. If the impact of uncorrected refractive errors is a
primary outcome measure of a study, then the  5.0 D
threshold is well justified based on the impact of 5.0 D of
uncorrected myopia on visual acuity. In such cases, astigma-
tism also should be considered, as less myopic spherical
equivalents with significant astigmatism may have a greater
impact on unaided visual acuity. However, high myopia is well
known to be associated with increased risks of visual loss, and,
to be clinically relevant, the threshold for high myopia should
FIGURE 3. Variation in the choice of thresholds for high myopia within epidemiologic studies (n¼ 59 studies).
FIGURE 2. Variation in the choice of the inclusion thresholds for myopia in terms of spherical equivalent within intervention studies (n ¼ 27
studies).
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reflect this risk. In terms of risk of uncorrectable visual
impairment, eyes more myopic than 6.00 D showed
considerably greater individual risk of visual loss than lower
degrees of myopia.18,19 However, a threshold of 6.00 D does
not consider that the incidence of a range of ocular diseases is
increased at much lower degrees of myopia.9 As proposed for
the definition of myopia, in cases where a different threshold
for high myopia is chosen for a study, investigators should
clearly indicate the methodologic and statistical reasons for
their choice. If there is a plausible risk of bias within a study
design due to the choice of threshold, a sensitivity analysis
should be done to quantify such potential biases. Results
should be reported using the standard threshold of 6 D, as
well as the chosen threshold to facilitate comparison of studies
and meta-analysis.
4.4 Proposed Definitions
Based on this analysis, the following quantitative definitions are
proposed. These definitions avoid the requirement for
objective refraction so as to be independent of technique,
but by making reference to relaxation of accommodation are
compatible with cycloplegic and standard clinical subjective
techniques. The definitions also relate to a single eye. An eye-
specific definition is required to allow different approaches to
analyzing data (e.g. by patient, eye, or an average of the two
eyes) and avoiding classification errors within study popula-
tions. All stated refractive error thresholds relate to the
spectacle-plane refraction.
Myopia: a condition in which the spherical equivalent
refractive error of an eye is  0.5 D when ocular
accommodation is relaxed.
High Myopia: a condition in which the spherical equivalent
refractive error of an eye is  6.00 D when ocular
accommodation is relaxed.
These definitions reflect common use within the field, but
as noted above their appropriateness is study-dependent.
Alternative thresholds are supported where appropriate, and
sensitivity analysis of the primary outcomes to alternative
thresholds are strongly recommended.
Refractions  0.5 and > 6.00 D may be appropriately
termed low myopia:
Low Myopia: a condition in which the spherical equivalent
refractive error of an eye is  0.5 and > 6.00 D when
ocular accommodation is relaxed.
Further subdivisions, such as intermediate or moderate
myopia, often are used, but with little consistency. Where such
terms are used in research studies, results also should be
reported at the standard thresholds to facilitate comparison
with other studies and facilitate meta-analysis.
5. THE CONCEPT OF PRE-MYOPIA
The above definitions all consider myopia as a static variable,
whereas most forms of myopia progress from onset for a
variable period. Currently, reducing the rate of progression is a
central goal of myopia research, but preventing the onset of
myopia is an even more valuable target. Such interventions will
require treatment of eyes before they become myopic. This
logically requires a definition of ‘‘pre-myopia’’ (i.e., a non-
myopic refraction in which a combination of risk factors and
the observed pattern of eye growth indicate a high risk of
progression to myopia). Longitudinal observational studies,
such as the Collaborative Longitudinal Evaluation of Ethnicity
and Refractive Error (CLEERE) study, have demonstrated that
eyes destined to become myopic show an accelerated pattern
of axial elongation several years before the onset of myopia.20
In the CLEERE Study, a refraction close to emmetropia in North
American children (7–13 years old) also has been shown to be
the best single predictor of future myopia.21 The exact
threshold varying with age from < þ0.75 D at age 6,  þ0.50
D at ages 7 to 8, þ0.25 D at ages 9 to 10, and  0 D at age 11
years. The predictive accuracy of baseline refraction alone is
likely to be insufficient to justify therapeutic interventions. In
another predictive model, Zhang et al.22 used baseline visual
acuity and biometric data to predict onset of myopia over a 3-
year period in 236 children from Xiamen in China (as a
learning set) and 1979 predominantly Chinese children in
Singapore (as a test set). They found that sex, visual acuity,
height, anterior chamber depth, lens thickness, vitreous
chamber depth, corneal curvature, and an interaction term
FIGURE 4. Variation in the choice of high myopia inclusion thresholds within intervention studies (n¼ 25 studies).
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between anterior chamber depth, lens thickness, and vitreous
chamber depth could be used to predict myopia onset. In the
future, it is expected that improved multifactorial risk scores
will be developed that provide sufficient predictive accuracy to
guide preventative therapies. Additional known risk factors
that may contribute to such risk scores include the number of
myopic parents, parental education, and identifiable environ-
mental risk factors, such as time spent indoors/outdoors,
activities and education, rate of change of axial length, rate of
change of refraction, and genomic risk scores.20,23–26 Even in
the absence highly predictive risk models, pre-myopia is a
useful concept at this stage and one that may promote further
research.
Proposed definition of Pre-myopia:
Pre-myopia – a refractive state of an eye of  0.75 D and >
0.50 D in children where a combination of baseline
refraction, age, and other quantifiable risk factors provide
a sufficient likelihood of the future development of myopia
to merit preventative interventions.
The above terms and definitions are summarized in Table 2.
6. THE STRUCTURAL COMPLICATIONS OF MYOPIA
Higher degrees of myopia are associated with a range of
structural changes within the retina, RPE, Bruch’s membrane,
choroid, optic nerve head, peripapillary area, optic nerve, and
sclera. Of all the terms included in Table 1 that relate to these
anatomical complications, ‘‘pathologic myopia’’ is the one that
already has gained a degree of international consensus. This is
the preferred term of the Meta-Analysis for Pathologic Myopia
(META-PM) Study Group who have recently published a
detailed photographic classification for myopic maculopathy.27
In addition, the term ‘‘degenerative high myopia’’ implies that
‘‘degeneration’’ is the only mechanism behind these changes,
whereas ‘‘pathologic myopia’’ appropriately avoids this confu-
sion.
The current version of the ICD (ICD11 for Mortality and
Morbidity Statistics, 2018) is notably out of step with this
growing consensus. There is no reference to ‘‘pathologic
myopia’’ within ICD-11 for Mortality and Morbidity Statistics
(2018). The term ‘‘degenerative myopia,’’ as used in ICD-10, is
changed within ICD-11 to ‘‘degenerative high myopia’’ (code
9B76) with the following list of synonyms: degenerative
myopia, progressive high degenerative myopia. Based on the
existing international consensus generated by the META-PM
consortium, this committee has proposed to the WHO that the
term ‘‘pathologic myopia’’ should replace the current ‘‘degen-
erative high myopia’’ in future amendments of ICD-11.
Pathologic Myopia: excessive axial elongation associated
with myopia that leads to structural changes in the posterior
segment of the eye (including posterior staphyloma, myopic
maculopathy, and high myopia-associated optic neuropathy)
and that can lead to loss of best corrected visual acuity.
It is important to note that this definition refers only to the
structural changes in the posterior segment and their visual
consequences. Pathologic myopia is sometimes equated with
high myopia, and descriptions may include a refractive (e.g.,
6.00, 5.00, or even 4.00 D in children) or axial length
threshold (e.g., > 25.5 or 26.5 mm).28 There are many reasons
why including refractive error or axial length is unhelpful.
Many studies have demonstrated that myopic maculopathy
extends to eyes of lower than5.00 or6.00 D, albeit at much
lower prevalence.29 A recent study from Taiwan shows
posterior staphyloma can be found in eyes with <26.5 mm
axial length.30 Inclusion of refraction within a concept, such as
pathologic myopia, also creates problems in relation to highly
myopic eyes that have had refractive procedures (e.g., corneal,
phakic intraocular lenses, clear lens, or cataract extraction). In
these cases, the refraction of the eye may be normal, but the
risk of pathologic myopia remains. Longitudinal studies also
have demonstrated that for a given refractive error, the
prevalence of pathologic myopia is age-dependent.8,31 There-
fore, a refractive definition for pathologic myopia would mean
that outcome or intervention studies could not be compared
reliably unless they were accurately age-matched.
6.1 Subdivisions of Pathologic Myopia
The complications of pathologic myopia affect a range of
structures and present clinically as distinct diagnostic entities.
Therefore, a series of definitions is required for all those
conditions that come under the umbrella of pathologic myopia.
As with other aspects of myopia, there is considerable variation
in terminology and definitions for such conditions. The Clinical
Modification of the existing ICD-10 system (ICD-10-CM)
includes five conditions that were classified as subdivisions
of ‘‘degenerative myopia:’’ choroidal neovascularization (CNV),
macular hole formation, retinal detachment, foveoschisis, and
other maculopathy. Other terms that commonly in use are:
myopic macular degeneration, myopic maculopathy, myopic
retinopathy, myopic chorioretinal atrophy, and myopic CNV.
The recent WHO publication on myopia included the term
‘‘myopic macular degeneration,’’ which includes several of the
ICD categories, and defined it as:
Myopic Macular Degeneration: a vision-threatening condi-
tion occurring in people with myopia, usually high myopia
that comprises diffuse, patchy macular atrophy with or
without lacquer cracks, CNV, and Fuchs’ spot.
The META-PM Study Group favors ‘‘myopic maculopathy’’
and provided a graded classification:
Myopic Maculopathy, Category 0: no myopic retinal
degenerative lesion.
Myopic Maculopathy, Category 1: tessellated fundus.
Myopic Maculopathy, Category 2: diffuse chorioretinal
atrophy.
Myopic Maculopathy, Category 3: patchy chorioretinal
atrophy.
Myopic Maculopathy, Category 4: macular atrophy.
These categories were defined with the aid of reference
photographs.27 The META-PM classification also provided for
three additional ‘‘plus’’ features: lacquer cracks, myopic CNV,
and Fuchs spot.
Myopic macular degeneration and myopic maculopathy are
in widespread use. As terms, they often are used interchange-
ably, but clear differences of opinion exist on the use of the
definitions. The WHO report stated that the META-PM
classification system of myopic maculopathy was too complex
for the purposes of data collection in population-based
surveys. The report went on to propose that for Rapid
Assessment of Avoidable Blindness (RAAB) surveys, which
typically are performed with simple instrumentation, a simpler
definition was required:
The definition of Myopic Macular Degeneration for the
purposes of RAAB surveys: A person who has vision
impairment and vision acuity that is not improved by
pinhole, which cannot be attributed to other causes, and
(1) the direct ophthalmoscopy records a supplementary
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lens < 5.00 D and shows changes such as ‘‘patchy
atrophy’’ in the retina or (2) the direct ophthalmoscopy
records a supplementary lens < 10.00 D.
The META-PM classification is a much more clinically
orientated schema that is ideally suited for natural history and
intervention studies. However, it is primarily a photographic
classification that does not provide a full description of all
aspects of pathologic myopia. The impact on visual function
may involve visual acuity, microperimetry, and electrophysi-
ologic assessments. The morphologic changes in the retina
and choroid can be defined in more detail by ocular
coherence tomography (OCT), retinal auto fluorescence
(AF), fluorescein angiography (FA), and indocyanine green
angiography (ICG). Changes in the sclera, such as staphyloma,
are best defined by a range of tools, including wide-field
OCT,32 magnetic resonance imaging (MRI),33 and wide-field
fundus imaging.34 Detailed studies of the pathophysiology
and etiology of pathologic myopia would likely involve such
additional investigative tools.
It is clear that a single definition for the structural
complications of pathologic myopia will not fit all potential
applications. In relation to the choice of myopic macular
degeneration (MMD) or myopic maculopathy (MM), neither
term is currently referenced within ICD-11 for Mortality and
Morbidity Statistics (2018). Achieving a consensus for one term
over the other is a challenging issue. The META-PM definition
of myopic maculopathy is a clinically oriented, diagnostic
classification, whereas the WHO report’s definition of myopic
macular degeneration is a more general description. Therefore,
we propose that MMD be used as the preferred categorical
term for the macular complications of pathologic myopia. This
general category then can usefully include specific sets of
diagnostic criteria, such as the META-PM classification and a
definition of MMD suitable for RAAB surveys. To cover the full
range of research applications we suggest that three such sub-
categories are required:
1. A RAAB-appropriate survey definition that uses the
limited data available from such study designs.
2. A standardized photographic classification for simple
natural history, cohort, or intervention studies.
3. A detailed structural and functional classification, includ-
ing a comprehensive range of clinical assessment and
imaging. This would be appropriate for studies address-
ing pathophysiology, etiology, intervention, and detailed
cohort studies.
The existing WHO and META-PM definitions satisfactorily
cover the first two tiers. This requires a descriptive term for the
RAAB-appropriate definition of MMD to differentiate it from
MMD as defined above. We propose that the term ‘‘presumed
myopic macular degeneration’’ would be appropriate. Within
this scheme, ‘‘myopic maculopathy’’ should be used as
specifically relating to the current META-PM photographic
classification scheme and its future iterations. In relation to the
third category, a range of more specific clinical terms is
required. Three specific clinical terms associated with macular
abnormalities are included in ICD-11 for Mortality and
Morbidity Statistics (2018) covering CNV in high myopia,
macular hole in high myopia, and foveoschisis in high myopia.
These terms by no means cover the full range of macula
complications seen within pathologic myopia. Therefore, it is
anticipated that as our understanding of the pathophysiology
of myopia develops, additional terms may be included within
this final category over time.
CNV, as a leading cause of visual loss in pathologic myopia,
certainly merits more detailed classification. The WHO
definition of MMD and the META-PM classification refer to
CNV and Fuchs’ spots, though these can be considered
different phases of the same process. Myopic CNV has three
phases: active, scar, and atrophic phases (also known as CNV-
related macular atrophy). A Fuchs’ spot represents the scar
phase of myopic CNV. The ICD-11 for Mortality and Morbidity
Statistics (2018) category refers to high myopia, inherently
introducing a refractive threshold. The phrase ‘‘CNV in
pathologic myopia’’ is recommended, since CNV occurring in
any degree of myopia may include idiopathic CNV and
punctate inner choroidopathy (PIC)-associated CNV. It is hoped
that a group, such as the META-PM Study Group, will address
this issue in the future to create a comprehensive classification
and grading for myopia-associated CNV.
Macular holes and retinoschisis at the posterior pole can
occur in various conditions, but are seen commonly in eyes
with other features of pathologic myopia. Therefore, they are
an appropriate part of the pathologic myopia spectrum. As
neither is specifically covered by the WHO definition of MMD,
nor the META-PM classification, a specific diagnostic category
is warranted. Within ICD-10-CM, the term ‘‘degenerative
myopia with foveoschisis’’ is used. This term is potentially
misleading as schisis seen in pathologic myopia often is
extrafoveal. Furthermore, OCT studies of pathologic myopia
have demonstrated that macular holes, lamellar macular holes,
and retinoschisis can coexist within a clinical spectrum that
also includes localized posterior retinal detachments.35 The
unifying factor in these complications is the existence of
vitreoretinal or intraretinal traction. Myopic traction maculop-
athy (MTM) is an alternative term that is growing in popularity
and more accurately encompasses the etiology of this set of
conditions.36
6.1.1 Myopic Traction Maculopathy. A combination of
macular retinoschisis, lamellar macula hole, and/or foveal RD
(FRD) in highly myopic eyes attributable to anterior tractional
forces arising from adherent vitreous cortex, epiretinal
membrane, internal limiting membrane, or retinal vessels,
and to posterior traction arising from a posterior staphyloma.
Macular Bruch’s membrane defects can develop in the
parafoveal and intrafoveal regions as part of the spectrum of
pathologic myopia. They are characterized by the lack of
Bruch’s membrane, RPE, and choriocapillaris, and show a
reduced or missing layer of retinal photoreceptors and of
Sattler’s layer in the choroid. A Bruch’s membrane defect may
arise de novo or in association with a widening lacquer crack,
and result in a localized absolute scotoma.
6.1.2 Nonmacular Structural Complications of Patho-
logic Myopia. Two nonmacular complications are seen
commonly in pathologic myopia: characteristic changes in
the optic nerve and retinal detachments. Neither fall within
the scope of the term MMD or the other terms discussed
above.
The excessive axial elongation seen in most highly myopic
eyes creates a range of changes in the optic nerve and
peripapillary region. These include peripapillary atrophy, tilted
optic discs,37 and acquired megalodiscs,38 Such changes, in
particular an enlargement of the optic disc and development
and enlargement of a peripapillary delta zone, have been linked
to the increased rate of glaucomatous or glaucoma-like optic
nerve damage observed in myopic eyes, or glaucoma-like optic
nerve damage observed in highly myopic eyes. A recent study
has shown that in eyes with myopia, but axial lengths  27.4
mm, glaucomatous optic neuropathy is associated with
elevated IOP. In more highly myopic eyes, with axial lengths
‡ 27.5 mm, IOP was not associated with glaucomatous optic
neuropathy.39 Therefore, it has been proposed that the optic
nerve damage observed in highly myopic eyes is not truly
glaucomatous. The phrase ‘‘myopia-associated glaucoma-like
optic neuropathy’’ has been used to describe this newly
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recognized condition. We propose that along with MTM, this
condition be considered as part of the spectrum of pathologic
myopia, with the following definition:
Myopia-associated glaucoma-like optic neuropathy: optic
neuropathy characterized by a loss of neuroretinal rim and
enlargement of the optic cup, occurring in highly myopic
eyes with a secondary macro disc or peripapillary delta
zone at a normal IOP.
Retinal detachments are more common in high myopia and
occur in younger ages in myopic than nonmyopic eyes. There
is a clear monotonic relationship between the incidence of
retinal detachment and refractive error extending to the low
myopia range.9 This increased risk is believed to relate to
changes in the peripheral retina, such as lattice degeneration,
as well as alterations in the composition and structure of the
vitreous. Although lattice degeneration has been reported to be
present in 60% of retinal detachments in eyes with high
myopia, it also is present in 20% of nonmyopic retinal
detachments.40 Furthermore, despite a much greater lifetime
risk of retinal detachment in eyes with myopia, and a younger
age at onset, the majority of retinal detachments occur in eyes
without myopia in most populations.41 As such, we propose
that retinal detachment, though a recognized and important
complication of myopia, should not be considered as part of
the spectrum of pathologic myopia.
The proposed definitions and terminology for the structural
complications of myopia are listed in Table 3.
7. DISCUSSION
Considering the variety of classifications, terminology and
thresholds in use in the field of myopia research, achieving
internationally accepted definitions is a challenging task. We
hope the definitions listed in Tables 2 and 3 will be acceptable
to a broad range of interests or, at the very least, start a process
that may lead to a meaningful consensus. In developing these
proposals, we have adopted a consensus and evidence-led
approach. We also have included the following considerations
that we regard as important criteria when adopting a clinical
definition:
 Relevance to nature of the research question.
 Relevance to the underlying biology of myopia.
 Acceptability to researchers in the field.
 Use for developing health policy.
In addition to the definitions and thresholds presented
above, we believe that it is important for future research that a
set of reporting standards be adopted within the myopia
research community. Acknowledging that some investigators
may not adopt these definitions, we strongly urge that, where
nonstandard qualifying terms are used to describe myopia,
such terms be clearly defined within any publications. In
addition, if the research question merits use of a refractive
error threshold that differs from the standard proposed
thresholds of 0.50 and 6.00 D, the results should be
presented for the chosen and standard thresholds to facilitate
comparison with other studies and meta-analysis, whenever
possible. If a plausible risk of classification bias exists in a
study, then a sensitivity analysis should be performed at more
myopic thresholds (e.g.,  0.75 or  1.0 D), whenever
possible.
This report has not considered techniques for measuring
refraction or for ensuring relaxation of accommodation, which
is essential for accurate measurement of refraction. Other
reports in this issue will review this in more detail, but
cycloplegia should be considered the ‘‘gold standard’’ for any
study of refraction including children.10 Where studies with
and without cycloplegia are compared, then an appropriate
analysis of potential bias should be included as part of any
publication.
The proposed thresholds in this report, as is standard in
myopia research, relate to spherical equivalent spectacle-
plane refraction on-axis. For most studies, this is adequate,
though again this relates to the research question. If retinal
defocus is an issue relevant to the study design (e.g., a study
examining the impact of defocus on choroidal thickness or an
intervention designed to influence eye growth through retinal
defocus), then the potential impact of astigmatism and off-
axis refraction must be considered. At a spherical equivalent
diagnostic threshold of 0.50 D modest amounts of astigma-
tism can create hyperopic defocus along one meridian,
thereby reversing the sign of retinal defocus. Similarly, small
degrees of relative peripheral hyperopia may reverse the sign
of retinal defocus off-axis in low myopia. In such cases myopia
must be defined in relation to each astigmatic meridian and by
retinal location.
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